Skip to main content
. 2015 Jan 27;4(1):e224. doi: 10.1038/mtna.2014.75

Figure 1.

Figure 1

Klkb1 lead short interfering RNA (siRNA) demonstrates in vivo selectivity as well as potency. Sprague Dawley rats received a single administration of Klkb1:(287) siRNA-lipid nanoparticle at the specified doses or nontargeting (nt) control at 0.5 mg/kg (n = 8 per group). Hepatic mRNA levels of Klkb1 and other coagulation factors were determined at day 7. Individual animals and group means with standard deviations are shown. *P < 0.1, **P < 0.01, ****P < 0.0001 compared to nt control.